Summit’s Litigation Analytics team contributed to a recent case regarding pharmaceutical patent infringement. The Medicines Company (TMC) pursued legal action against Mylan Pharmaceuticals, Inc. regarding their Abbreviated New Drug Application (ANDA), which sought FDA approval to manufacture, use, and sell a generic version of TMC’s patented drug Angiomax®. TMC’s patent is in place until 2028.
Dr. Alan Salzberg served as an expert witness in this case, providing statistical analysis and professional testimony during trial. The judgment, which was released October 27 2014, noted that Dr. Salzberg exposed flawed calculations on the part of the opponent, and provided more substantive testimony.
Judge Amy St. Eve, in the U.S. District Court for the Northern District of Illinois, ruled in favor of TMC for two judgments: that the patent is being infringed upon, and that the patent claims are valid and enforceable.